How many drugs treat Diarrhea due to E. Coli?

Drug Landscape tracks 6 marketed treatments for Diarrhea due to E. Coli (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Diarrhea due to E. Coli?

Most recent: xifaxan — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/diarrhea-due-to-e-coli.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Diarrhea due to E. Coli — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diarrhea due to E. Coli (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Diarrhea due to E. Coli, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Xifaxan	rifaximin	Bausch Health	Rifamycin Antibacterial [EPC]	Nuclear receptor subfamily 1 group I member 2, Bacterial DNA-directed RNA polymerase
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1
Rifaximine	Rifaximine	Ain Shams University		Nuclear receptor subfamily 1 group I member 2, Bacterial DNA-directed RNA polymerase
xifaxan	xifaxan	Children's Hospital Los Angeles		Nuclear receptor subfamily 1 group I member 2, Bacterial DNA-directed RNA polymerase
Ciprofloxacine	Ciprofloxacine	Poitiers University Hospital		DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-19 — xifaxan · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 2 drugs in Diarrhea due to E. Coli
Ain Shams University · 1 drug in Diarrhea due to E. Coli
Assistance Publique - Hôpitaux de Paris · 1 drug in Diarrhea due to E. Coli
Bausch Health · 1 drug in Diarrhea due to E. Coli
Bayer AG · 1 drug in Diarrhea due to E. Coli
Children's Hospital Los Angeles · 1 drug in Diarrhea due to E. Coli
Poitiers University Hospital · 1 drug in Diarrhea due to E. Coli

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Diarrhea due to E. Coli:

Cite this brief

Drug Landscape (2026). Diarrhea due to E. Coli — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/diarrhea-due-to-e-coli. Accessed 2026-06-10.

Diarrhea due to E. Coli full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing